Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 8, 2019

Bio-Thera receives Chinese approval for Humira biosimilar

Chinese pharmaceutical company Bio-Thera Solutions has received approval from the country’s National Medical Products Administration (NMPA) for Qletli, a biosimilar to AbbVie’s Humira (adalimumab).

Chinese pharmaceutical company Bio-Thera Solutions has received approval from the country’s National Medical Products Administration (NMPA) for Qletli, a biosimilar to AbbVie’s Humira (adalimumab).

Qletli is an anti-TNF- α monoclonal antibody. The drug secured approval for all eligible indications of Humira, including rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.

It is said to be the first Humira biosimilar approved in China. Qletli is available in prefilled syringes for subcutaneous administration.

Bio-Thera Solutions CEO Shengfeng Li said: “The NMPA approval of Qletli is a very important milestone for our biosimilar portfolio, providing a new affordable treatment option for patients in China with several types of autoimmune diseases.

“Qletli is the first biosimilar from our portfolio to receive regulatory approval. We look forward to seeking approvals of Qletli in other regulated markets around the world.”

The China NMPA approval was based on a comprehensive data package, including analytical, non-clinical, pharmacokinetics, pharmacodynamics and clinical data.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

A Phase III clinical trial of the drug met its primary endpoint with no clinically meaningful differences in safety, immunogenicity and efficacy when compared to adalimumab.

Last year, Humira fetched $20bn in sales, according to Reuters. AbbVie’s drug lost patent protection in Europe, where many cheaper biosimilar versions of the drug have been launched.

Humira’s US patents are set to expire in 2023. Multiple pharmaceutical companies have already secured the US Food and Drug Administration’s (FDA) approval for Humira biosimilars, including Samsung Bioepis and Novartis subsidiary Sandoz.

In addition to Qletli, Bio-Thera is developing several proposed biosimilars, including those of Avastin and Actemra / RoActemra, which are undergoing global Phase III trials.

The company is also working on biosimilar versions of Simponi and Stelara.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU